{"product_id":"retatrutide-from-first-dose-to-full-protocol","title":"Retatrutide: From First Dose to Full Protocol","description":"\u003cstyle\u003e\n  @import url('https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,400;0,600;1,400\u0026family=Jost:wght@300;400;500;600\u0026display=swap');\n\n  * { margin: 0; padding: 0; box-sizing: border-box; }\n\n  body {\n    background: transparent;\n    color: #e8e0d0 !important;\n    font-family: 'Jost', sans-serif;\n    font-weight: 300;\n    font-size: 15px;\n    line-height: 1.75;\n  }\n\n  .wrap {\n    max-width: 720px;\n    margin: 0 auto;\n    padding: 48px 24px;\n  }\n\n  \/* HOOK *\/\n  .hook {\n    border-left: 3px solid #b5a98a;\n    padding-left: 20px;\n    margin-bottom: 40px;\n  }\n\n  .hook p {\n    font-family: 'Cormorant Garamond', serif;\n    font-size: 22px;\n    line-height: 1.5;\n    color: #e8e0d0 !important;\n  }\n\n  \/* SECTION LABEL *\/\n  .label {\n    font-size: 10px;\n    font-weight: 600;\n    letter-spacing: 0.15em;\n    text-transform: uppercase;\n    color: #b5a98a !important;\n    margin-bottom: 10px;\n  }\n\n  \/* DIVIDER *\/\n  .divider {\n    border: none;\n    border-top: 1px solid #3a3a32;\n    margin: 36px 0;\n  }\n\n  \/* BODY TEXT *\/\n  p {\n    margin-bottom: 16px;\n    color: #c8c0b0 !important;\n  }\n\n  \/* WHAT'S INSIDE *\/\n  .inside-grid {\n    display: grid;\n    grid-template-columns: 1fr 1fr;\n    gap: 12px;\n    margin: 20px 0;\n  }\n\n  .inside-item {\n    background: #1a1a18;\n    color: #e8e0d0;\n    padding: 16px 18px;\n    font-size: 13px;\n    line-height: 1.6;\n  }\n\n  .inside-item strong {\n    display: block;\n    font-weight: 500;\n    font-size: 12px;\n    letter-spacing: 0.05em;\n    text-transform: uppercase;\n    color: #b5a98a;\n    margin-bottom: 4px;\n  }\n\n  \/* WHO THIS IS FOR *\/\n  .for-block {\n    background: #252520;\n    border-left: 3px solid #b5a98a;\n    padding: 20px 24px;\n    margin: 20px 0;\n  }\n\n  .for-block p {\n    margin-bottom: 8px;\n    font-size: 14px;\n    color: #c8c0b0 !important;\n  }\n\n  .for-block p:last-child { margin-bottom: 0; }\n\n  \/* MECHANISM TABLE *\/\n  .mech-table {\n    width: 100%;\n    border-collapse: collapse;\n    margin: 20px 0;\n    font-size: 13px;\n  }\n\n  .mech-table th {\n    background: #1a1a18;\n    color: #e8e0d0;\n    text-align: left;\n    padding: 10px 14px;\n    font-weight: 500;\n    font-size: 11px;\n    letter-spacing: 0.08em;\n    text-transform: uppercase;\n  }\n\n  .mech-table td {\n    padding: 10px 14px;\n    border-bottom: 1px solid #3a3a32;\n    color: #c8c0b0 !important;\n    vertical-align: top;\n  }\n\n  .mech-table tr:last-child td { border-bottom: none; }\n\n  .mech-table tr:nth-child(even) td { background: #222220; }\n\n  .tag {\n    display: inline-block;\n    font-size: 10px;\n    font-weight: 600;\n    letter-spacing: 0.1em;\n    text-transform: uppercase;\n    padding: 2px 7px;\n    margin-right: 4px;\n  }\n\n  .tag-glp { background: #d4e4f2; color: #1a3a5a; }\n  .tag-gip { background: #f2e8d4; color: #5a3a1a; }\n  .tag-gcg { background: #d4ecd4; color: #2a5a2a; }\n\n  \/* DIAGNOSTIC SECTION *\/\n  .diagnostic {\n    background: #1a1a18;\n    color: #e8e0d0;\n    padding: 28px;\n    margin: 20px 0;\n  }\n\n  .diagnostic .label { color: #b5a98a; margin-bottom: 16px; }\n\n  .q-row {\n    display: flex;\n    gap: 12px;\n    margin-bottom: 14px;\n    align-items: flex-start;\n  }\n\n  .q-num {\n    font-family: 'Cormorant Garamond', serif;\n    font-size: 28px;\n    line-height: 1;\n    color: #b5a98a;\n    flex-shrink: 0;\n    width: 28px;\n  }\n\n  .q-text {\n    font-size: 13px;\n    line-height: 1.6;\n    color: #c8c0b0;\n    padding-top: 4px;\n  }\n\n  .results-grid {\n    display: grid;\n    grid-template-columns: 1fr 1fr;\n    gap: 1px;\n    background: #3a3a32;\n    margin: 20px 0;\n  }\n\n  .result-box {\n    background: #222220;\n    padding: 18px;\n  }\n\n  .result-label {\n    font-size: 10px;\n    font-weight: 600;\n    letter-spacing: 0.12em;\n    text-transform: uppercase;\n    margin-bottom: 6px;\n  }\n\n  .result-label.timing { color: #e0b870; }\n  .result-label.lean { color: #7ec87e; }\n  .result-label.infra { color: #e08080; }\n  .result-label.patience { color: #70a8e0; }\n\n  .result-box p {\n    font-size: 12.5px;\n    line-height: 1.6;\n    color: #a8a090 !important;\n    margin: 0;\n  }\n\n  \/* AUDIT MENTION *\/\n  .audit-mention {\n    border: 1px solid #3a3a32;\n    padding: 24px;\n    margin: 36px 0 0;\n  }\n\n  .audit-mention .label { margin-bottom: 8px; }\n\n  .audit-mention p {\n    font-size: 13.5px;\n    color: #c8c0b0 !important;\n    margin-bottom: 0;\n  }\n\n  \/* DISCLAIMER *\/\n  .disclaimer {\n    font-size: 11px;\n    color: #666 !important;\n    text-align: center;\n    margin-top: 36px;\n    letter-spacing: 0.04em;\n  }\n\n  @media (max-width: 540px) {\n    .inside-grid { grid-template-columns: 1fr; }\n    .results-grid { grid-template-columns: 1fr; }\n  }\n\u003c\/style\u003e\n\n\u003cdiv class=\"wrap\"\u003e\n\n  \u003c!-- HOOK --\u003e\n  \u003cdiv class=\"hook\"\u003e\n    \u003cp\u003eMost researchers switching to retatrutide are not prepared for a compound that changes what hunger means. The confusion is not a dosing problem. It is an interpretation problem.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003cp\u003eRetatrutide: From First Dose to Full Protocol is built around one problem that no other guide addresses directly. Researchers who understand semaglutide or tirzepatide will misread almost every signal retatrutide produces until they understand what the glucagon receptor actually does and why the experience of this compound is structurally different from everything that came before it. This guide covers the receptor mechanics, the injection timing argument, the staged build logic, and the most expensive mistakes researchers make in weeks one through sixteen.\u003c\/p\u003e\n\n  \u003chr class=\"divider\"\u003e\n\n  \u003c!-- WHAT'S INSIDE --\u003e\n  \u003cdiv class=\"label\"\u003eWhat this guide covers\u003c\/div\u003e\n  \u003cdiv class=\"inside-grid\"\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eReceptor Mechanics\u003c\/strong\u003e\n      What GLP-1, GIP, and glucagon are actually doing and why physical hunger rising does not mean the compound stopped working. The interpretation framework every researcher needs before the first injection.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eInjection Frequency\u003c\/strong\u003e\n      What weekly, twice weekly, and daily structures actually produce in terms of fat loss intensity, tolerability, and variance. Why the right frequency is not about convenience.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eMorning Injection Logic\u003c\/strong\u003e\n      Why timing is a mechanism decision not a scheduling preference. The cortisol alignment argument, the thermogenic window, and the appetite coverage case all explained in plain language.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eThe Four Stall Patterns\u003c\/strong\u003e\n      Output timing failure, lean mass loss, infrastructure collapse, and impatience. Each one looks like a stall. Only one calls for adding a compound. The guide shows how to tell them apart.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eTesamorelin Decision Logic\u003c\/strong\u003e\n      What Tesamorelin actually does, when it becomes rational to add it, and what conditions disqualify it. The minimum stable window before introduction and what happens when that window is skipped.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eWhy Ipamorelin Cannot Be Used Alone\u003c\/strong\u003e\n      The two-signal system that governs GH release and why ipamorelin without a GHRH layer produces a real but disproportionate result. The sequencing logic that makes the combination work.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eWeek 1 to Week 16 Roadmap\u003c\/strong\u003e\n      What is happening at each phase, what it means, and what not to do in response to it. The normalization misread at weeks four through six is where most protocol mistakes are made.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eComparison: Tesamorelin vs CJC no DAC vs HGH\u003c\/strong\u003e\n      Not a strength ranking. A mechanism match. Each option explained by what problem it solves and who it is actually for — not by theoretical potency.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eStaged Build vs Everything at Once\u003c\/strong\u003e\n      Why building in stages is not caution but the only approach that produces usable data. What starting everything simultaneously costs the researcher in attribution and troubleshooting clarity.\n    \u003c\/div\u003e\n    \u003cdiv class=\"inside-item\"\u003e\n      \u003cstrong\u003eInfrastructure and Support Layers\u003c\/strong\u003e\n      Why protein, sleep, and training volume are upstream of any compound's ability to help. The section that explains most stack disappointments without adding a single new compound.\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\n  \u003chr class=\"divider\"\u003e\n\n  \u003c!-- WHO THIS IS FOR --\u003e\n  \u003cdiv class=\"label\"\u003eWho this is for\u003c\/div\u003e\n  \u003cdiv class=\"for-block\"\u003e\n    \u003cp\u003eResearchers who are switching to retatrutide from a prior GLP-1 and finding the experience different enough to feel wrong even when it is working correctly.\u003c\/p\u003e\n    \u003cp\u003eResearchers who have stalled in weeks four through six and are considering dose escalation or compound addition before identifying which of the four stall patterns they are actually in.\u003c\/p\u003e\n    \u003cp\u003eResearchers running a stacked protocol who cannot tell which compound is responsible for the results they are seeing or the side effects they are managing.\u003c\/p\u003e\n    \u003cp\u003eAnyone who wants to understand the decision logic behind adding Tesamorelin or ipamorelin before making that move and adding a variable they cannot yet interpret.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003chr class=\"divider\"\u003e\n\n  \u003c!-- RECEPTOR TABLE --\u003e\n  \u003cdiv class=\"label\"\u003eThe three-receptor framework\u003c\/div\u003e\n  \u003cp\u003eRetatrutide is not a stronger GLP-1. Each receptor does a different job. Understanding which signal is active at any given moment is what separates a correct read from an expensive mistake.\u003c\/p\u003e\n\n  \u003ctable class=\"mech-table\"\u003e\n    \u003cthead\u003e\n      \u003ctr\u003e\n        \u003cth\u003eReceptor\u003c\/th\u003e\n        \u003cth\u003eWhat it does\u003c\/th\u003e\n        \u003cth\u003eMost common misread\u003c\/th\u003e\n      \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n      \u003ctr\u003e\n        \u003ctd\u003e\u003cspan class=\"tag tag-glp\"\u003eGLP-1\u003c\/span\u003e\u003c\/td\u003e\n        \u003ctd\u003eSlows gastric emptying, suppresses food noise, reduces the reward-driven pull toward eating. The intake side of the protocol.\u003c\/td\u003e\n        \u003ctd\u003eAssuming this is the only relevant signal and judging the full experience by GLP-1 standards alone.\u003c\/td\u003e\n      \u003c\/tr\u003e\n      \u003ctr\u003e\n        \u003ctd\u003e\u003cspan class=\"tag tag-gip\"\u003eGIP\u003c\/span\u003e\u003c\/td\u003e\n        \u003ctd\u003eImproves tolerability of the GLP-1 signal and plays a role in fat cell insulin sensitivity. The layer that makes the protocol more livable at higher output pressure.\u003c\/td\u003e\n        \u003ctd\u003eTreating tirzepatide and retatrutide as interchangeable because both carry this receptor.\u003c\/td\u003e\n      \u003c\/tr\u003e\n      \u003ctr\u003e\n        \u003ctd\u003e\u003cspan class=\"tag tag-gcg\"\u003eGlucagon\u003c\/span\u003e\u003c\/td\u003e\n        \u003ctd\u003eSignals the liver to release stored energy, raises resting metabolic rate, increases thermogenic output, and drives physical hunger. The output side of the protocol.\u003c\/td\u003e\n        \u003ctd\u003eTreating rising physical hunger as failure when food noise is simultaneously suppressed. Both signals present at once is the mechanism working correctly.\u003c\/td\u003e\n      \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n  \u003c\/table\u003e\n\n  \u003chr class=\"divider\"\u003e\n\n  \u003c!-- DIAGNOSTIC FLOWCHART PREVIEW --\u003e\n  \u003cdiv class=\"diagnostic\"\u003e\n    \u003cdiv class=\"label\"\u003eFast-entry diagnostic — preview\u003c\/div\u003e\n    \u003cdiv class=\"q-row\"\u003e\n      \u003cdiv class=\"q-num\"\u003e1\u003c\/div\u003e\n      \u003cdiv class=\"q-text\"\u003eIs the fatigue or disrupted sleep concentrated in the 24 to 48 hours after injection and is the injection currently in the evening or at bedtime?\u003c\/div\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"q-row\"\u003e\n      \u003cdiv class=\"q-num\"\u003e2\u003c\/div\u003e\n      \u003cdiv class=\"q-text\"\u003eIs food noise lower than before starting the protocol even if physical hunger is present? These are two different signals and the answer changes the diagnosis entirely.\u003c\/div\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"q-row\"\u003e\n      \u003cdiv class=\"q-num\"\u003e3\u003c\/div\u003e\n      \u003cdiv class=\"q-text\"\u003eIs the physique flattening while the scale still moves, or has the scale genuinely stalled? These are different stall patterns with different correct responses.\u003c\/div\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"q-row\"\u003e\n      \u003cdiv class=\"q-num\"\u003e4\u003c\/div\u003e\n      \u003cdiv class=\"q-text\"\u003eHas the foundation been at a stable dose and timing structure for at least six to eight weeks before any support layer is being considered?\u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- RESULTS GRID --\u003e\n  \u003cdiv class=\"results-grid\"\u003e\n    \u003cdiv class=\"result-box\"\u003e\n      \u003cdiv class=\"result-label timing\"\u003ePattern — Output Timing Failure\u003c\/div\u003e\n      \u003cp\u003eThe glucagon peak is landing on rest days or during sleep. Adjust injection timing or frequency before evaluating anything else. This is a timing problem not a compound problem.\u003c\/p\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"result-box\"\u003e\n      \u003cdiv class=\"result-label lean\"\u003ePattern — Lean Mass Loss\u003c\/div\u003e\n      \u003cp\u003eThe scale is moving but the physique is flattening. Confirm protein intake and training stimulus first. If both are adequate and lean mass is still declining this is the only pattern where Tesamorelin has a clear rational job.\u003c\/p\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"result-box\"\u003e\n      \u003cdiv class=\"result-label infra\"\u003ePattern — Infrastructure Failure\u003c\/div\u003e\n      \u003cp\u003eResults declined at a specific point in time. Sleep dropped or protein fell below target or a high-stress period began. The compound is still working. The substrate it is working on has degraded. Restore first.\u003c\/p\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"result-box\"\u003e\n      \u003cdiv class=\"result-label patience\"\u003ePattern — Normalization Misread\u003c\/div\u003e\n      \u003cp\u003eEarly results were strong. Weeks four through six have slowed. Nothing else changed. The acute response phase ended and the sustainable baseline has established. Food noise should still be lower than baseline. If it is, the protocol is working.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\n  \u003chr class=\"divider\"\u003e\n\n  \u003c!-- AUDIT MENTION --\u003e\n  \u003cdiv class=\"audit-mention\"\u003e\n    \u003cdiv class=\"label\"\u003eIf the guide identifies the pattern but not the source\u003c\/div\u003e\n    \u003cp\u003eThis guide gives researchers the framework to read what their protocol is producing and the decision logic to respond correctly at each stage. There is a category of stall it cannot reach — where multiple variables have shifted at the same time, where the interpretation has already been complicated by simultaneous compound changes, or where the pattern is present but the cause is not visible from inside the protocol. That level of diagnostic resolution is what the Protocol Audit is built for.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- AUDIT CTA --\u003e\n  \u003cdiv style=\"text-align: center; margin: 32px 0 20px;\"\u003e\n    \u003ca href=\"https:\/\/project-theo.com\/pages\/protocol-audit\" style=\"display: inline-block; background: #e8e0d0; color: #1a1a18 !important; text-decoration: none; font-family: 'Jost', sans-serif; font-size: 12px; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; padding: 16px 36px;\"\u003eView the Protocol Audit\u003c\/a\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- DISCLAIMER --\u003e\n  \u003cp class=\"disclaimer\"\u003eFor educational and research purposes only  |  Not medical advice  |  Not for human use guidance  |  Project Theo\u003c\/p\u003e\n\n\u003c\/div\u003e","brand":"PROJECT THEO","offers":[{"title":"Default Title","offer_id":43330567209019,"sku":null,"price":39.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0657\/5102\/3675\/files\/rn-image_picker_lib_temp_1d4825b1-ceb8-4cf1-bd57-15dce341cf61.png?v=1774836143","url":"https:\/\/project-theo.com\/products\/retatrutide-from-first-dose-to-full-protocol","provider":"PROJECT THEO","version":"1.0","type":"link"}